SAB Biotherapeutics, Inc.

NASDAQ:SABS

Biotechnology

Healthcare
$3.20 -0.53%

-$0.02 today

Market cap
$288.28M
Beta
0.53
P/E (TTM)
3.0
EPS (TTM)
-$0.16
52W Low $1.85High $5.15

Volume 0.89M

Average 0.76M

SABS Deferred Tax Liabilities

Taxes owed in future periods because of timing differences between accounting and tax rules.

SAB Biotherapeutics, Inc.NASDAQ: SABS

Deferred Tax Liabilities · Q2 FY2026 · quarter ended Jun 2026

Deferred tax liabilities remains negative

Q2 FY2026 deferred tax liabilities was $0, compared with $0 a year earlier.

Context

  • Deferred tax liabilities amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Deferred tax liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoJun 2025
$0— since
Deferred Tax Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Tax Liabilities history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Tax Liabilities vs competitors

How SABS compares with its peers on the latest reported figures

  • SABS's Jun 2026 deferred tax liabilities of $0 is the highest of the 5 companies compared; the peer median is $0.
  • Deferred tax liabilities amounts to 0.0% of total assets for SABS, versus a peer median of 0.0%.
SABS Competitors Peer median
Deferred Tax Liabilities for SABS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SABSSAB Biotherapeutics, Inc.Jun 2026$0 ——0.0%
QTTBQ32 Bio Inc.Mar 2026$0 ——0.0%
ANTXAN2 Therapeutics, Inc.Mar 2026$0 ——0.0%
VRCAVerrica Pharmaceuticals Inc.Mar 2026$0 ——0.0%
BOLDBoundless Bio, Inc.Mar 2026$0 ——0.0%
Peer median (excluding SABS) $0——0.0%

Competitors are the stored peer set for SABS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents33.21M15.05M56.57M8.9M10.5M
Short-term Investments00011.86M86.09M
Net Receivables8.01M5.56M054.96K946.78K
Inventory00000
Other Current Assets6.34M002.98M3.51M
Total Current Assets50.19M22.1M58.91M23.79M101.05M
Property, Plant & Equipment (Net)30.95M28.34M24.68M19.92M19.4M
Goodwill00000
Intangible Assets00000
Long-term Investments000046.89M
Tax Assets00000
Other Non-current Assets(1)467.69K350.23K482.1K5.46M
Total Non-current Assets30.95M28.81M25.03M20.4M71.76M
Total Assets81.14M50.9M83.94M44.2M172.81M
Account Payables4.46M3.68M945.93K1.69M3.15M
Short-term Debt1.8M772.67K1.05M275.85K951.37K
Tax Payables216.25K50K40K00
Deferred Revenue100K01.32M00
Other Current Liabilities8.7M8.1M4.49M01.55M
Total Current Liabilities26.46M14.99M10.81M7.98M10.68M
Long-term Debt0541.64K000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities10.72M320.93K11.77M6.39M5.64M
Total Non-current Liabilities16.14M4.85M15.83M10.25M10.63M
Total Liabilities42.59M19.85M26.64M18.23M21.32M
Common Stock4.35K5.09K9299354.77K
Retained Earnings(29.13M)(47.87M)(90.06M)(124.17M)(110.9M)
Accumulated OCI0026.42K(135.41K)186.51K
Other Stockholders Equity00000
Minority Interest00000
Total Equity38.55M31.06M57.3M25.97M151.49M
Total Debt8.52M5.93M5.91M4.67M5.95M
Net Debt(24.69M)(9.12M)(50.66M)(4.23M)(4.55M)

SAB Biotherapeutics, Inc.

NASDAQ:SABS

Intrinsic Alpha fair value

Locked

Current Price

$3.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.